Stockreport

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update [Yahoo! Finance]

iBio, Inc.  (IBIO) 
NASDAQ:AMEX Investor Relations: ir.ibioinc.com
PDF Presented non-human primate data for our potentially first-in-class Activin E antibody, IBIO-610, which may enable only twice-yearly dosing for the treatment of obesity [Read more]